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Abstract
Treatment for childhood acute lymphoblastic leukemia (ALL), which includes CNS prophylaxis, is associated with
central and peripheral neurotoxicity. The purpose of the present study was to analyze the effects of chemotherapy on
various levels of visuomotor control in survivors of childhood ALL treated without cranial irradiation, and to
identify risk factors for possible deficits. Visuomotor function was compared between children after treatment for
ALL (n5 34), children after treatment for Wilms tumor, which consists of non-CNS directed chemotherapy (n5
38), and healthy controls (n5 151). Three tasks were administered: a simple visual reaction time task and two tasks
measuring visuomotor control with one requiring a higher level of cognitive control than the other. Visuomotor
deficits were detected only in the ALL group, with poorer performance restricted to the condition requiring the
highest level of control. Significant risk factors for poorer performance were female gender and a short time since
end of treatment, and a trend was found for a young age at diagnosis. A high cumulative methotrexate dose was an
adverse predictive factor in girls. The results indicate that chemotherapy-induced central neurotoxicity in childhood
ALL treatment is associated with higher order visuomotor control deficits. Girls appear to be particularly
vulnerable. (JINS, 2005, 11, 554–565.)
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INTRODUCTION
Long-term survival in childhood acute lymphoblastic leu-
kemia (ALL) has improved substantially due to evolution
of multi-agent chemotherapy protocols and to the introduc-
tion of prophylactic treatment of the central nervous system
(CNS) (Pui et al., 1998). The 5-year overall survival curves
have now reached 80% in developed countries (Gatta et al.,
2002). This has resulted in an increasing interest in the late
effects of disease and treatment on physical, mental and
social well-being of the survivors. Several elements of ther-
apy for ALL may affect the function of the central and
peripheral nervous system, and cognitive deficits (e.g.,
Anderson et al., 2000; Brown et al., 1992; Butler et al.,
1994; Moleski, 2000; Ochs et al., 1991) as well as gross
and fine motor impairments (Galea et al., 2004; Harila-
Saari et al., 2001; Lehtinen et al., 2002; Reinders-Messelink
et al., 1996; Vainionpaa, 1993; Wright et al., 1998) have
been reported in survivors of childhood ALL. CNS-directed
treatment is a standard component of therapy for ALL. Evi-
dence of a detrimental effect of prophylactic cranial irradi-
ation on neurocognitive function in children with ALL
(Cousens et al., 1988; Jankovic et al., 1994; Meadows et al.,
1981) has resulted in reduction of the use of cranial irradi-
ation and the development of chemotherapy-only protocols
with the same or better rate of treatment success (Kamps
et al., 2002; Tubergen et al., 1993).
The current study was conducted to assess possible visuo-
motor deficits in survivors of childhood ALL treated with
chemotherapy only. There is limited knowledge of long-
term visuomotor outcome in children with ALL. The major-
ity of reports on this subject include studies performed during
or shortly after end of treatment. Studies on motor function
in children with ALL have demonstrated that, while gross
Reprint requests to: Annemieke Buizer, M.D., Department of Pediat-
rics, VU University Medical Center, De Boelelaan 1117, 1081 HV Amster-
dam, The Netherlands. E-mail: ai.buizer@vumc.nl
Journal of the International Neuropsychological Society (2005), 11, 554–565.
Copyright © 2005 INS. Published by Cambridge University Press. Printed in the USA.
DOI: 10.10170S1355617705050666
554
motor skills may improve after treatment, fine motor prob-
lems in children with ALL may increase over time (Reinders-
Messelink et al., 1999). Vincristine has been implicated as
the cause of these motor impairments, because of its toxic
effect on the peripheral nervous system. Vincristine-induced
neurotoxicity is dose-related (Carbone et al., 1963) and
causes a peripheral, symmetric mixed sensory–motor, and
autonomic polyneuropathy which is more marked distally
(Gidding et al., 1999). CNS toxicity from intravenous vin-
cristine is rare, most likely due to poor penetration through
the intact blood–brain barrier (Kellie et al., 2002). Cortico-
steroids may contribute to motor problems in children treated
for ALL as they can cause proximal myopathy (DeAngelis
et al., 1991). Both peripheral neuropathy and myopathy in
children with ALL have been found to regress quickly after
end of treatment, although subtle motor deficits have been
reported up to 2 years after cessation of chemotherapy
(Harila-Saari et al., 1998; Reinders-Messelink et al., 1996).
Motor and somatosensory evoked potential studies have
shown that there is a central nervous system component in
motor and sensory dysfunction in children with ALL (Harila-
Saari et al., 1998, 2001; Vainionpaa et al., 1997). CNS-
directed chemotherapy for ALL, consisting of intrathecal
methotrexate, alone or in combination with cytarabine and
corticosteroids, and of systemic methotrexate and cortico-
steroids, is associated with central neurotoxicity (Kerr et al.,
2001; Surtees et al., 1998). Various studies have demon-
strated visuomotor deficits in relationship with other cog-
nitive impairments in children with ALL after treatment
with chemotherapy only (Copeland et al., 1996; Kingma
et al., 2001; Lesnik et al., 1998).
Motor and cognitive development are closely inter-
related and, when cognitive development is disturbed, motor
development is often also adversely affected (Diamond,
2000). This is supported by evidence from children with
neurodevelopmental disorders as attention deficit hyper-
activity disorder and autism, in which cognitive deficits are
frequently accompanied by visuomotor problems (Kalff
et al., 2003; Muller et al., 2003). That CNS disorders in
children may lead to visuomotor deficits has also been estab-
lished in children with phenylketonuria (Huijbregts et al.,
2003), periventricular brain injury (Downie et al., 2003;
Jakobson et al., 2001), (mild) closed head injury (Heitger
et al., 2004), HIV infection (Frank et al., 1997) and early
hydrocephalus (Erickson et al., 2001). Measures of visuo-
motor skills are possibly the instruments most sensitive to
cerebral damage (Frank et al., 1997; Heitger et al., 2004).
Many motor tasks employed in these studies involve some
degree of cognitive (executive) control.
As risk factors for poorer cognitive performance after
childhood ALL treated with chemotherapy only, female gen-
der (Brown et al., 1998; Von der Weid et al., 2003; Waber
et al., 1992) and a young age at diagnosis (Copeland et al.,
1996; Von der Weid et al., 2003) have been reported.
To assess the nature of possible visuomotor deficits in
survivors of ALL, visuomotor tasks requiring varying lev-
els of cognitive control were employed. A tracking task,
involving the drawing of a circle within predefined borders,
largely relies on automatic processing. A pursuit task in
which a randomly moving target has to be followed, demands
higher level cognitive control as it involves non-automatized
movements that require concurrent planning and execution.
Survivors of a Wilms tumor, a childhood cancer of the kid-
ney, were included in the study. These children received a
different chemotherapy regimen, not directed at the CNS.
Healthy controls were also included.
We sought to determine whether visuomotor function was
impaired in survivors of childhood ALL treated with che-
motherapy only. We hypothesized that the central effects of
chemotherapy for ALL on visuomotor function have the
greatest impact on the condition requiring the highest level
of control. Because children with a Wilms tumor did not
receive chemotherapy with central neurotoxic properties
we would not expect to observe these deficits in this group.
To determine risk factors for possible visuomotor deficits
in survivors of ALL, the association between outcome and
different components of chemotherapy was examined, as
well as the role of patient and disease characteristics.
PARTICIPANTS AND METHODS
Research Participants and
Treatment Protocols
We studied children in complete remission from ALL who
had finished treatment at least one year before. The chil-
dren with ALL were recruited from the VU University Med-
ical Center. Children were excluded if they suffered a pre-
existent neurological or psychiatric disorder or a learning
disability, had presented with CNS leukemia, received cra-
nial irradiation or suffered a relapse. All other children who
had been treated for ALL with chemotherapy only at this
institution and who were between 4.5 and 18 years of age at
the time of the study were eligible to participate. Of the 42
children who met the criteria for inclusion in the study, 36
agreed to participate and 34 (81%) completed a full assess-
ment. Reasons for refusal were reluctance of parents to bur-
den the children with tests for research or lack of time. The
characteristics of the non-participants regarding demo-
graphic, disease, or treatment variables did not differ from
the participating children. From both participating study
centers, the VU University Medical Center and the Eras-
mus Medical Center0Sophia Children’s Hospital, in total
38 children with a Wilms tumor were included, also at least
1 year after end of treatment, and matched as closely as
possible for age and gender to the children with ALL. The
children with a Wilms tumor formed a clinical control group
who had also experienced cancer and chemotherapy, but no
CNS-directed treatment. Siblings of children with ALL (n5
20) and of children with a Wilms tumor (n 5 23) were
enlisted in a sibling control group. The healthy control group
consisted of 108 healthy, age-matched schoolchildren, among
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them schoolmates of the children with ALL or a Wilms
tumor. From these three groups, children were excluded in
case of a history of a neurological or psychiatric disorder or
a learning disability. Informed consent was obtained follow-
ing the guidelines of the ethical committees of both treat-
ment centers.
The children with ALL had been treated according to the
consecutive Dutch Childhood Leukemia Study Group
(DCLSG) ALL treatment protocols 6 to 9 (Kamps et al.,
1999, 2002; Veerman et al., 1996), and were diagnosed
between 1985 and 1999. Patients were stratified into risk
groups based on leukemia cell load, cell phenotype and
spread of the disease. Patients with standard risk ALL were
treated according to standard treatment protocols while inter-
mediate and high risk patients, who were at higher risk for
relapse of the disease, received intensified treatment. The
criteria for risk group classification varied across the dif-
ferent protocols. In our study, 15 children had been treated
according to the ALL standard treatment protocols and 19
according to intensified protocols, these numbers corre-
sponding with the distribution of risk groups nationwide
(Kamps et al., 1999, 2002; Veerman et al., 1996). CNS-
directed treatment consisted of intrathecal chemotherapy
and of systemically administered methotrexate and cortico-
steroids. Intrathecal chemotherapy consisted of “triple ther-
apy”: methotrexate, prednisolone, and cytarabine (DCLSG
protocol ALL 6, 8 and 9), or of methotrexate alone (DCLSG
protocol ALL 7). Intrathecal drug doses varied little between
risk groups and the various protocols. Regarding poten-
tially neurotoxic chemotherapy, the greatest difference
between standard ALL treatment and intensified ALL treat-
ment, was the dose of systemic, intravenously adminis-
tered, methotrexate. Standard ALL treatment included
medium dose intravenous methotrexate (three or four doses
of 2 g0m2, depending on the protocol), whereas intensified
ALL treatment entailed high dose intravenous methotrexate
(ranging from four doses of 3 g0m2 to six doses of 5 g0m2 ).
Corticosteroids used were dexamethasone and0or predni-
sone. DCLSG protocols ALL 6 and 9 were dexamethasone
based whereas protocols ALL 7 and 8 were prednisone based.
Other drugs used were vincristine, l-asparaginase,
6-mercaptopurine in standard treatment protocols and addi-
tionally cytarabine, cyclofosfamide and daunorubicine in
intensified treatment protocols. Total duration of ALL treat-
ment was 18 to 24 months.
Children with a Wilms tumor were treated with pre-
operative chemotherapy, followed by a nephrectomy, sys-
temic chemotherapy and when necessary with local radiation
therapy, according to SIOP protocols 9 and 93-01 (D’Angio,
1983; Tournade et al., 2001). Children with a Wilms tumor
did not receive CNS-directed treatment. Chemotherapy con-
sisted of vincristine and actinomycine-D in favorable strat-
ified cases. In patients with advanced stage disease and0or
unfavorable histology, anthracyclines, ifosfamide, etopo-
side and carboplatinum were added. Chemotherapy contin-
ued for 3 to 9 months after diagnosis, depending on stage
and histology.
Neurological Status
Clinical neurological examination, performed in most sur-
vivors (25 children with ALL and 18 children with a Wilms
tumor) by one medical doctor to assess motor function (based
on Touwen’s neurological examination (Touwen, 1979)),
revealed no pareses, ataxia, or tremor in any of the children.
Deep tendon reflexes were low to absent in 2025 survivors
of ALL (8%) and 2018 survivors of a Wilms tumor (11%).
On only one item a significant difference was found between
the survivor groups: slight dysdiadochokinesia was recorded
in 6 out of 25 (24%) of survivors of ALL (1 standard risk
patient and 5 high-risk patients) while no dysdiadochokine-
sia was detected in the survivors of a Wilms tumor ( p 5
.025). Interviews with the parents of all participating survi-
vors of ALL or a Wilms tumor revealed no significant dif-
ferences between these two groups regarding frequency of
reported neurological symptoms. None of the symptoms
were reported to be major or to affect daily life importantly.
Most children were in normal schools, with two survivors
of ALL and no survivors of a Wilms tumor following spe-
cial education programs. Parents of 32% of children with
ALL reported some kind of mild motor problem in their
children versus 29% of parents of children with a Wilms
tumor. Mild problems with handwriting and0or drawing were
most frequently reported (in 19% and 16% of cases, respec-
tively), followed by mild gross motor problems (18% and
8%, respectively).
Visuomotor Tasks (Figure 1)
Three visuomotor subtests of a computerized test battery,
the Amsterdam Neuropsychological Tasks (ANT), were
administered (De Sonneville, 1999). The ANT program was
designed to measure the various aspects of attention and
information processing. The tests used in this study have
previously been shown to be sensitive for detection of spe-
cific visuomotor deficits, for example in children with atten-
tion deficit hyperactivity disorder (Kalff et al., 2003) and
children with phenylketonuria (Huijbregts et al., 2003). The
tests were performed using a notebook computer with a 140
TFT color screen and a symmetrical computer wheel mouse.
The tests were administered in a quiet room in the outpa-
tient clinic, at home or at school. Every child had the oppor-
tunity to practice the tasks in a separate session preceding
the actual test moment. A simple visual reaction time test
(baseline speed ) was used as a reference task. The tracking
task involves execution of a movement that can be planned
in advance, requiring a low level of controlled processing.
The pursuit task involves close pursuit of a target moving
unpredictably, in random directions, demanding a much
higher level of controlled processing.
Baseline speed
This task involves minimal cognitive effort. The subject is
required to press a mouse-key as quickly as possible when
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a fixation cross in the center of the computer screen changes
into a white square (imperative signal). Following the
response, the fixation cross reappears. The time interval
between a response and the next signal onset varies ran-
domly between 500–2500 ms to prevent anticipation strat-
egies. There are separate trials (n5 32) for the right and left
index finger.
Tracking
This task measures accuracy and stability of movement along
a planned trajectory. The subject is required to move the
cursor in between an outer circle (radius 8.5 cm) and an
inner circle (radius 7.5 cm) presented on the computer screen
by moving the computer mouse cursor which is shaped as a
Fig. 1. Visuomotor tasks.
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tiny dot. The movement is executed with the preferred hand;
in clockwise direction for the right hand and in counter-
clockwise direction for the left hand. To assess perfor-
mance on this task, the position of the mouse cursor is
continuously recorded, using the midline as reference. The
mean radial distance of the cursor to the midline per circle
segment (1060th of the circle) is computed, resulting in 60
deviation scores. The standard deviation (SD) of these 60
deviation scores from the midline is computed as a measure
for stability of movement. The percentage of the circle posi-
tions that are inside the borders of the circle and result from
a movement in the correct direction, is used as a measure of
the accuracy of performance on this task.
Pursuit
This task measures accuracy and stability of movement along
an unpredictable trajectory. The subject is required to con-
tinuously trace a target star moving randomly on the screen
by moving the computer mouse with the preferred hand
over a time period of 60 s. While motor demands are iden-
tical to the tracking task, cognitive demands are higher. As
the trajectory of the target is unpredictable, this task demands
the concurrent planning and execution of movements. The
ANT program computes the mean distance between the
mouse cursor and the moving target per second resulting in
60 deviation scores. The mean distance and the standard
deviation of the deviation scores are calculated and taken
as a measure of accuracy and stability of performance,
respectively.
Data Analysis
Mean reaction time for the preferred hand in the baseline
speed task, and the measures for accuracy and stability on
the tracking and pursuit tasks were transformed into z scores
using age-appropriate norm values, obtained from the ANT
program manual (De Sonneville, 2003). Z scores were
derived from 1-year age bands and drawn from a compari-
son sample of 2712 for the baseline speed task, 773 for the
tracking task and 585 for the pursuit task.
In a first step, mean z scores were compared using two-
way ANOVAs with group and gender as the between-
subjects variables. The siblings of the survivors and the
schoolchildren were taken together as one healthy control
group, because the comparison of their results using ANOVA
showed no differences between the two groups on any of
the measures (.10 , p , .98 and .01 , d , .28). This left
three groups in the analyses: survivors of ALL, survivors of
a Wilms tumor and healthy controls. Contrast analyses, using
a simple contrast with the healthy controls as a reference
group, were performed to examine the differences between
controls and survivors of a Wilms tumor and between con-
trols and survivors of ALL, respectively. Gender was used
as a between-subjects variable based on previous reports of
gender differences with regard to cognitive sequelae of ALL.
Effect sizes for group contrasts and gender effects were
computed as Cohen’s d, which represents the magnitude of
mean differences in standard deviation units, with d 5 .2
indicating small, d 5 .5 moderate, and d . .8 indicating
large effect sizes (Cohen, 1988). Univariate analyses were
performed per task measure, with a set at .018 after Bon-
ferroni adjustment for correlated multiple comparisons
(Uitenbroek, 2003).
In a second step, the risk factors for poorer visuomotor
performance in survivor groups were examined using mul-
tiple regression analyses. To identify predictors of task per-
formance, exploratory correlation analyses were performed
between the outcome measures and various patient, dis-
ease, and treatment factors as independent variables. Besides
gender, these were age at diagnosis, time since end of treat-
ment and cumulative doses of chemotherapy with neuro-
toxic properties (intravenous vincristine, intravenous,
intrathecal and oral methotrexate, intravenous and intrathe-
cal cytarabine, intrathecal prednisolone, oral dexametha-
sone and oral prednisone). Variables that correlated at r .
.20 with an outcome measure were entered as predictor
variables into a hierarchical multiple regression model.
Patient factors were entered in the first step, disease and
treatment factors in the second step and possible interaction
terms in the third step, with a set at 0.05. Predictor vari-
ables were centered around the mean to prevent problems
with multicollinearity (Aiken and West, 1991).
RESULTS
Characteristics of the study children and doses of poten-
tially neurotoxic chemotherapy are depicted in Table 1. Mean
age at diagnosis was significantly lower and mean time
elapsed since end of treatment was significantly longer in
survivors of a Wilms tumor than in survivors of ALL in our
study. The boy0girl ratio did not differ significantly between
groups. There were no significant differences between che-
motherapy doses between boys and girls in either survivor
group. There were no associations between any of the find-
ings on neurological examination and the ANT outcome
measures in the survivor groups. In Figure 2, mean z scores
for all task measures are depicted per group, for boys and
girls separately. The results of the two-way ANOVAs, with
group and gender as between subjects variables, indicate no
significant main or interaction effects on the measures of
baseline speed, tracking accuracy and tracking stability. The
effect sizes for all group and gender contrasts on these mea-
sures were small. Differences did emerge, however, for the
measures of pursuit accuracy and pursuit stability. For pur-
suit accuracy there was a significant main effect of group
[F(2,217)5 5.23, p5 .006]. Contrast analysis showed sig-
nificantly worse results for pursuit accuracy in survivors of
ALL compared to controls (contrast estimate, CE: 2.64,
p 5 .001, d 5 .50), while performance of survivors of a
Wilms tumor on this measure did not differ from controls
(CE: 20.11, p 5 .56, d 5 .11). A trend was found for the
main effect of gender [F(1,217)5 5.14, p5 .024, d5 .32].
There was no interaction effect of Group3Gender on pur-
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suit accuracy ( p5 .37). For pursuit stability, the main effect
of group [F(2,217)5 6.34, p5 .002] was significant. Con-
trast analysis showed that the contrast between survivors of
ALL and controls was significant for pursuit stability (CE:
2.83, p5 .001, d5 .46), while survivors of a Wilms tumor
did not differ from controls (CE: 2.07, p 5 .76, d 5 .06).
The main effect of gender was also significant [F(1,217)5
12.21, p5 .001, d5 .22], with girls performing worse than
boys. There was a non-significant trend for an interaction
effect of Group3Gender [F(2,217)5 2.93, p5 .056]. The
Group3 Gender interaction effect on pursuit stability was
significant when contrasting survivors of ALL with con-
trols [F(1,181)5 5.90, p5 .016], indicating that the group
difference between survivors of ALL and controls was par-
ticularly evident in girls.
The results of the hierarchical multiple regression analy-
ses of risk factors for worse performance on the pursuit task
within the ALL group are presented in Table 2. In the final
model for the pursuit stability measure, main effects indi-
cate female gender and a shorter time since treatment as
significant risk factors for worse performance. A non-
significant trend level effect was found for age at diagnosis.
A trend was also found for the two-way interaction effect of
Gender 3 Cumulative Systemic Methotrexate Dose. Post-
hoc simple slope analysis of the two-way interaction revealed
a significant relation between a higher cumulative systemic
methotrexate dose and worse performance on pursuit sta-
bility in girls ( p 5 .046), while there was no significant
relation between methotrexate dose and performance in boys
(see Figure 3). Gender and age at diagnosis were trend level
predictors of accuracy on the pursuit task in the ALL group.
The direction of these trend level main effects indicated
female gender and a young age at diagnosis as risk factors
for worse performance. Within the Wilms tumor group, none
of the entered independent variables were associated with
any of the task outcome measures on a significant or trend
level.
DISCUSSION
This study provides evidence for subtle visuomotor control
deficits in children after treatment for ALL with chemother-
apy only. Compared to healthy controls including siblings
of the survivors, the survivors of ALL showed poorer per-
formance on a visuomotor pursuit task. There were no defi-
ciencies on a tracking task or in simple motor reaction time.
No visuomotor deficits were found in survivors of a Wilms
tumor, who received a less intensive and presumably less
neurotoxic chemotherapy regimen.
That worse visuomotor performance in survivors of child-
hood ALL is restricted to the condition requiring the high-
est level of cognitive control, supports our hypothesis on
the central effects of chemotherapy for ALL on visuomotor
function. The pursuit task involves a relatively high level of
cognitive control, as concurrent planning and execution of
movement is required while moving the computer mouse
along a trajectory that is unpredictable. Motor demands;Ta
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namely, manipulating the mouse cursor across the screen,
are similar in the pursuit task and in the tracking task. Cog-
nitive demands are much lower during the tracking task,
however, as the trajectory of movement with the computer
mouse can be planned in advance. The drawing of a circle
becomes an increasingly automated action throughout devel-
opment, also making the tracking task easier to perform
than the pursuit task. The baseline speed task measures sim-
ple reaction time, rendering low motor and cognitive
demands.
The results we report are in accordance with results of
studies using the same visuomotor tasks as in our study in
different populations with CNS disorders. In a study on
children with attention-deficit0hyperactivity disorder, high-
level visuomotor control deficits as measured with the pur-
suit task were linked to behavioral problems (Kalff et al.,
2003). In children with phenylketonuria, affecting biochem-
ical parameters, differences between patients and healthy
controls were significantly greater on the pursuit task than
on the tracking task (Huijbregts et al., 2003). In adult mul-
tiple sclerosis patients, performance on the pursuit task was
found to correlate with disease severity (De Sonneville et al.,
2002).
Visuomotor control involves occipito–parietal and fron-
tal cerebral areas (Hamzei et al., 2002; Wise et al., 1997),
as well as the cerebellum and the basal ganglia (Miall et al.,
2001) and their interconnections. Through the dorsal stream
of visual areas in the parietal lobe, localization and move-
ment are perceived, crucial for performance of visuomotor
tasks. The parietal cortex and frontal motor areas are linked
by cortico–cortical connections, as well as by a subcortical
pathway through the cerebellum (Glickstein, 2000). The
frontal cortex has a critical role in the attentional control of
unpracticed movements (Richer et al., 1999). Involvement
of the prefrontal region has been shown to increase with
increasing attention load during visuomotor action (Cham-
inade & Fonlupt, 2003). The myelination of the prefrontal
cortex and of cerebellar–prefrontal networks has a pro-
Fig. 2. Z scores for visuomotor task outcome by group and gender (M, SE). Note: a lower (negative) z score indicates
a worse performance.
Fig. 3. Regression lines for relations between cumulative i.v. meth-
otrexate dose and pursuit stability as moderated by gender in ALL
survivors, at mean values for age at diagnosis and time since treat-
ment (two-way interaction). Notes: b5 unstandardized regression
coefficient, i.e. simple slope. A lower (negative) z score indicates
worse performance. Indicated values for cumulative i.v. metho-
trexate dose on the x-axis are minimum and maximum values in
the ALL study group.
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tracted course during childhood and adolescence (Fuster,
2002; Klingberg et al., 1999). Because less mature brain
areas are believed to be more susceptible to damage than
areas that are more mature, the prefrontal cortex and
cerebellar–prefrontal networks may have a large window of
vulnerability during development (Ciesielksi et al., 1997).
Lesnik et al. (1998) demonstrated cerebellar-frontal sub-
system changes on structural MRI in children with ALL
treated before the age of 5 with chemotherapy only. Meth-
otrexate is the cytostatic drug mostly implicated in central
neurotoxicity in children with ALL (Shuper et al., 2000).
Cerebral white matter changes (Chu et al., 2003; Dambska
& Laure-Kamionowska, 1999; Surtees et al., 1998), neuro-
nal damage (Chu et al., 2003; Quinn et al., 1998; Van Gool
et al., 2000) and neurotransmitter abnormalities (Madhy-
astha et al., 2002) have been described in children treated
with chemotherapy.
That performance of the survivors of ALL on the pursuit
task is impaired in the absence of major neurological defi-
cits, indicates it is a marker of more subtle neurological
impairment. This is in accordance with the notion that mea-
sures of visuomotor skills may be sensitive indicators of
cerebral damage (Frank et al., 1997; Heitger et al., 2004).
The frequency of reported neurological symptoms and signs
corresponds with the results of other studies on neurologi-
cal function in children treated for ALL with chemotherapy
only, with gross motor difficulties, abnormal deep tendon
reflexes, dysdiadochokinesia and0or fine motor problems
being reported in 30–50% of children after the end of treat-
ment (Harila-Saari et al., 1998; Harila-Saari et al., 2001;
Reinders-Messelink et al., 1996) and still detectable in
8–30% of children 5 years after cessation of therapy
(Lehtinen et al., 2002). Results of sensory and motor evoked
potential studies suggest that neurological abnormalities are
associated with demyelinative injury to central as well as
peripheral nerve tracts (Harila-Saari et al., 2001; Lehtinen
et al., 2002; Vainionpaa et al., 1997). In their studies on
motor performance in children with ALL, Reinders-
Messelink et al. (1996, 1999, 2001) found that problems
with balance and gross motor performance occurred mainly
during treatment and improved with time, while fine motor
problems appeared after treatment. As vincristine neuropa-
thy is acute and decreases with time (Postma et al., 1993), it
is postulated that these fine motor problems may be due to
methotrexate neurotoxicity, which can have a late onset and
run a chronic course (Vezmar et al., 2003).
Worse performance on the pursuit task in survivors ofALL
is associated with female gender and a short time since end
of treatment in our study. A trend is found for a young age at
diagnosis as a risk factor. There is also a trend for an inter-
action between gender and cumulative systemic methotrex-
ate dose. In girls, a higher cumulative systemic methotrexate
dose is significantly associated with less stable performance
on the pursuit task. To our knowledge, this is the first time
that a direct relation between methotrexate dose and visuo-
motor task performance is reported in survivors ofALLtreated
with chemotherapy only, albeit only in girls.Ta
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Greater vulnerability of girls to chemotherapy-induced
central neurotoxic effects of chemotherapy has been noted
in several studies on neuropsychological sequelae of ALL
treatment (Brown et al., 1998; Von der Weid et al., 2003;
Waber et al., 1992). Notably, in a behavioral study in rats,
female animals were more sensitive to the effects of thera-
pies involving methotrexate than males (Mullenix et al.,
1994). Gender differences in brain maturation may explain
divergent vulnerabilities between girls and boys. Increase
in white matter during childhood has been demonstrated to
be smaller in girls than in boys (De Bellis et al., 2001),
which could result in girls being more susceptible to the
damaging effects of chemotherapy on myelin.
The negative association of time since end of treatment
with performance on the pursuit task may indicate that the
effects of chemotherapy in children with ALL on visuomo-
tor function ameliorate with time, however, this should be
confirmed in a study with a longer follow-up time. Although
age at diagnosis as a predictor of pursuit accuracy and of
pursuit stability does not reach significance in our study,
our finding of a trend level effect suggests that a young age
at diagnosis as a risk factor for worse visuomotor perfor-
mance in survivors of ALL may be worthy of further study.
This association would be in accordance with previous stud-
ies that report a younger age at diagnosis as a risk factor for
worse cognitive performance in survivors of ALL (Cope-
land et al., 1996; Von der Weid et al., 2003), suggesting a
greater vulnerability of less mature brain structures to neuro-
toxic insult (Ciesielski et al., 1999).
Although it is difficult to take into account the effects of
all treatment variables, it appears from our results that the
role of vincristine-related peripheral neurotoxicity in per-
formance on the pursuit task may be limited in survivors of
ALL past 1 year after end of treatment. If peripheral neu-
ropathy were likely to play an important part, performance
on the tracking task would have been expected to be simi-
larly impaired, as motor manipulation demands are compa-
rable to the pursuit task even though cognitive demands are
less. We also found no correlation between cumulative vin-
cristine dose and accuracy or stability of movement during
the pursuit task in survivors of ALL or a Wilms tumor,
while neuropathy due to vincristine has previously been
demonstrated to be correlated with cumulative dose (Ver-
stappen et al., 2003).
The findings of this study should be interpreted in the
light of some limitations. First, although the sample size
was sufficient for detecting differences between groups even
with moderate effect sizes, the size of the ALL group was
relatively small for analyzing all possible risk factors. Some
predictors (age at diagnosis, interaction of Gender3Cumu-
lative systemic methotrexate dose) in the regression analy-
ses did not exceed trend level although the size of their
coefficients suggests these factors are not trivial. Also, the
variations between the treatment protocols employed for
the children in this study, in combination with the complex
nature of these treatments, limit definitive interpretation of
the exact role of all treatment components, their possible
interactions and mode of administration. Another issue is
that the mean interval between end of treatment and assess-
ment was longer in survivors of a Wilms tumor than in
survivors of ALL. As a consequence, the absence of visuo-
motor deficits in the Wilms tumor group should be inter-
preted with some caution.
In conclusion, our results demonstrate that survivors of
ALL treated with chemotherapy only, still show subtle visuo-
motor deficits after having finished treatment at least 1 year
earlier. Worse visuomotor performance is restricted to con-
ditions where higher order control is required, and is likely
due to central neurotoxic effects of the treatment. The
finding that girls seem to be more vulnerable to central
neurotoxic effects of chemotherapy underscores the
results of previous studies and should be subject of further
investigation.
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